Drug Abuse Survey with Confirmation, Panel 9, Urine
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
This assay was designed to test for and confirm by gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) the most common classes of drugs of abuse.
This test uses the simple screening technique described under IDOAU / Drug Abuse Survey, Urine, which involves immunologic testing for drugs by class. All positive screening results are confirmed by GC-MS (positive alcohol by GC) or LC-MS/MS, and quantitated, before a positive result is reported.
This test represents the coupling of IDOAU / Drug Abuse Survey, Urine with an automatic confirmation of all positive results by the definitive assay available and described elsewhere (eg, AMPHU / Amphetamines Confirmation, Urine).
Detecting drug abuse involving alcohol, amphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiates, phencyclidine, and tetrahydrocannabinol
This test is intended to be used in a setting where the test results can be used definitively to make a diagnosis
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Not intended for use in employment-related testing.
The test does not screen for drug classes other than those listed above. More comprehensive screening is available using the serum or urine drug screens (DSS / Drug Screen, Prescription/OTC, Serum or PDSU / Drug Screen, Prescription/OTC, Urine).
For situations where chain-of-custody is required, a Chain-of-Custody Kit (Supply T282) is available.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Screening cutoff concentrations
Amphetamines: 500 ng/mL
Barbiturates: 200 ng/mL
Benzodiazepines: 200 ng/mL
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
Ethanol: 30 mg/dL
Methadone: 150 ng/mL
Opiates: 300 ng/mL
Phencyclidine: 25 ng/mL
Tetrahydrocannabinol carboxylic acid: 20 ng/mL
This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.
Clinical References Provides recommendations for further in-depth reading of a clinical nature
1. Physician's Desk Reference (PDR). 60th edition. Montvale, NJ, Medical Economics Company, 2006
2. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th edition. Edited by LL Bruntman. New York, McGraw-Hill Book Company, 2006
3. Langman LJ, Bechtel L, Holstege CP. In Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Edited by CA Burtis, ER Ashwood, DE Bruns. Chapter 35. WB Saunders Co, 2011, pp 1109-1188